skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Proton Therapy in Pediatric Skull Base and Cervical Canal Low-Grade Bone Malignancies

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1]; ; ;  [1];  [2];  [1];  [3]; ; ; ;  [1];  [4]
  1. Centre de Protontherapie de l'Institut Curie a Orsay, Campus Universitaire, Orsay (France)
  2. University Hospital, Caen Cyceron Laboratory, Caen (France)
  3. Department of Pediatric Oncology, Institut Gustave-Roussy, Villejuif (France)
  4. Department of Pediatric Neurosurgery, University Hospital Necker-Enfants Malades, Paris (France)

Purpose: To evaluate outcomes and tolerance of high-dose photon and proton therapy in the management of skull base and cervical canal primary bony malignancies in children. Patients and Methods: Thirty children were treated postoperatively with high-dose photon-proton (29 patients) or protons-only (1 patient) radiotherapy. Twenty-six patients had chordomas (CH), 3 had low-grade chondrosarcomas (CS), and 1 had an aggressive chondroma (AC). The mean age was 12.8 years. At the time of radiation, all but 1 patient had a gross residue. The anatomic sites affected were skull base (n 16), cervical canal (n = 1), or both (n = 13). Mean total dose was 68.4 cobalt Gray equivalents, conventionally fractionated. Results: With a mean follow-up of 26.5 months, 5 of 30 children failed locally: 5 of 5 lesions were CH, 5 of 5 patients had experienced pain at presentation (p = 0.03), and 4 of 5 had cervical extension (p = 0.07). The 5-year overall survival/progression-free survival rates for CS and CH were 100%/100% and 81%/77%, respectively. Side effects were scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. Acute toxicity ranged between 0 and 2. Late toxicity of radiotherapy was severe in 1 patient (Grade 3 auditory) and minor or mild in the rest of the population (7 patients with Grade 2 pituitary dysfunction). Conclusions: High-dose combined fractionated photon-proton therapy is well tolerated in children and allows excellent local control with minimal long-term toxicity.

OSTI ID:
21124302
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 71, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2008.02.043; PII: S0360-3016(08)00353-2; Copyright (c) 2008 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Effectiveness and Safety of Spot Scanning Proton Radiation Therapy for Chordomas and Chondrosarcomas of the Skull Base: First Long-Term Report
Journal Article · Sun Nov 15 00:00:00 EST 2009 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21124302

Spot Scanning Proton Therapy for Malignancies of the Base of Skull: Treatment Planning, Acute Toxicities, and Preliminary Clinical Outcomes
Journal Article · Sat Nov 01 00:00:00 EDT 2014 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21124302

Spot-Scanning Proton Radiation Therapy for Pediatric Chordoma and Chondrosarcoma: Clinical Outcome of 26 Patients Treated at Paul Scherrer Institute
Journal Article · Mon Jul 01 00:00:00 EDT 2013 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21124302